Skip to content
Screener

Alnylam Pharmaceuticals ALNY Q1 2026 earnings

Reported April 30, 2026 · Before market open

Revenue$1.2BBeat by $51.7M
EPS$1.51Beat by $0.64
Revenue estimate$1.1B
EPS estimate$0.87

Next report

Oct 29, 2026 (in 2 months)
Revenue estimate$1.4B
EPS estimate$2.19

Financials

Q1 2026

Income statement

See full
Revenue$1.2B+96.4%
Gross profit$959.7M+83.1%
Operating income$268.6M+1,386%
Net income$206.0M+1,229%
EPS (diluted)$1.51+1,179%

Balance sheet

See full
Cash & equivalents$1.7B+67.5%
Total debt$263.7M-4.5%
Total equity$1.1B+832%
Total assets$5.1B+21.7%

Cash flow

See full
Operating cash flow$70.5M+160%
CapEx$21.8M+143%
Free cash flow$48.7M+138%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$43.88B+25.6%
Enterprise value$42.43B+24.1%
P/E87.4×—
P/S10.2×-4.6×

Profitability

See full
Gross margin81%-5.3pp
Operating margin17.5%+14.4pp
Net margin11.7%+8.0pp
FCF margin15%+12.7pp

Returns & leverage

See full
Return on equity84.4%—
Debt / equity0.2×-2.1×
Current ratio3.1×+0.1×

FAQ

When did Alnylam Pharmaceuticals report Q1 2026 earnings?
Alnylam Pharmaceuticals (ALNY) reported Q1 2026 earnings on April 30, 2026 before market open.
What were Alnylam Pharmaceuticals's Q1 2026 revenue and EPS?
Alnylam Pharmaceuticals reported revenue of $1.2B and eps of $1.51 for Q1 2026.
Did Alnylam Pharmaceuticals beat estimates in Q1 2026?
Revenue beat the consensus estimate of $1.1B by $51.7M. EPS beat the consensus estimate of $0.87 by $0.64.
How did Alnylam Pharmaceuticals's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 96.4% from $594.2M a year earlier.
Where can I find Alnylam Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-028601) and the 10-Q periodic report (0001628280-26-028605) directly on SEC EDGAR. The filing index links above go to sec.gov.